SCHEMBL4820959

SCHEMBL4820959

[O]C1OC(=O)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 3/20 0.40
ALOX15 P16050 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
NPC1 O15118 1/20 0.40
KDM4E B2RXH2 3/20 0.39
GAA P10253 1/20 0.39
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
GFER P55789 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29791776 0.80 ALDH1A1 (0.59) ALDH1A1MEN1POLBKMT2AHSD17B10
SCHEMBL13329531 0.74 ALDH1A1 (0.53) ALDH1A1MEN1POLBKMT2AHSD17B10
SCHEMBL12991705 0.74 ALDH1A1 (0.53) ALDH1A1MEN1POLBKMT2AHSD17B10
SCHEMBL14019428 0.74 ALDH1A1 (0.53) ALDH1A1MEN1POLBKMT2AHSD17B10
SCHEMBL6770346 0.74 ALDH1A1 (0.53) ALDH1A1MEN1POLBKMT2AHSD17B10
SCHEMBL3037795 0.74 ALDH1A1 (0.53) ALDH1A1MEN1POLBKMT2AHSD17B10
SCHEMBL868796 0.74 ALDH1A1 (0.53) ALDH1A1MEN1POLBKMT2AHSD17B10
SCHEMBL2668143 0.74 ALDH1A1 (0.53) ALDH1A1MEN1POLBKMT2AHSD17B10
SCHEMBL10542289 0.74 ALDH1A1 (0.53) ALDH1A1MEN1POLBKMT2AHSD17B10
SCHEMBL304982 0.74 ALDH1A1 (0.53) ALDH1A1MEN1POLBKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2497475-A1 Treatment of laminitis with platelet aggregation inhibitors Dussler, Sabine (DE) 2012-09-12 EP claimed
EP-1562903-A4 MUCIN SYNTHESIS INHIBITORS GENAERA CORP (US) 2006-09-20 EP claimed
EP-1562903-A2 MUCIN SYNTHESIS INHIBITORS Genaera Corporation (US) 2005-08-17 EP claimed
WO-2004043392-A2 MUCIN SYNTHESIS INHIBITORS GENAERA CORPORATION (US) 2004-05-27 WO claimed
US-20030236220-A1 MUCIN SYNTHESIS INHIBITORS GENAERA CORPORATION (US) 2003-12-25 US claimed
US-5994356-A ANTICOAGULANT KARL THOMAE (DE) 1999-11-30 US claimed
EP-0809626-B1 PRODUCTION OF ENANTIOMERICALLY ENRICHED ORTHO-SUBSTITUTED ALPHA, ALPHA DIAROMATIC METHANOLS NOVARTIS AG (CH) 1999-09-01 EP claimed
EP-0542411-B1 TETRAHYDROTHIENOPYRIDINE DERIVATIVES, FURO AND PYRROLO ANALOGS THEREOF AND THEIR PREPARATION AND USES FOR INHIBITING BLOOD PLATELET AGGREGATION SANKYO CO (JP) 1998-08-12 EP claimed
US-5700801-A ANTIINFLAMMATORY AGENTS, BONE DISORDERS KARL THOMAE, GMBH (DE) 1997-12-23 US claimed
EP-0809626-A1 PRODUCTION OF ENANTIOMERICALLY ENRICHED ORTHO-SUBSTITUTED $g(a),$g(a)-DIAROMATIC METHANOLS Novartis AG (CH) 1997-12-03 EP claimed
US-4410520-A ANGIOTENSION CONVERTING ENZYME INGIBITOR, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1983-10-18 US claimed
EP-0003960-B1 6-SUBSTITUTED THIA-AZA-COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CIBA-GEIGY AG (CH) 1983-06-29 EP claimed
EP-0082113-A1 2-Aminobytyl-2-penem derivatives, process for their preparation and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1983-06-22 EP claimed
EP-0072352-A1 Benzazepin-2-ones, process for their preparation, pharmaceutical preparations containing these compounds and the compounds for therapeutical use CIBA-GEIGY AG (CH) 1983-02-16 EP claimed
WO-1982003860-A1 DERIVATIVES OF 1,4-THIAZANE-CARBOXYLIC ACID,PREPARATION AND UTILIZATION THEREOF AND COMPOSITIONS CONTAINING SAME GILLET CLAUDE 1982-11-11 WO claimed
EP-0061765-A1 Beta-Lactams E.R. SQUIBB & SONS, INC. (US) 1982-10-06 EP claimed
US-4301279-A Process for the production of 3-hydroxy compounds CIBA-GEIGY CORPORATION (US) 1981-11-17 US claimed
US-4293462-A Process for the manufacture of enol derivatives, and intermediates CIBA-GEIGY CORPORATION (US) 1981-10-06 US claimed
US-4232151-A ANTIBIOTICS SHIONOGI & CO., LTD. (JP) 1980-11-04 US claimed
EP-0003960-A1 6-Substituted thia-aza-compounds, their preparation and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1979-09-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236220-A1 MUCIN SYNTHESIS INHIBITORS MUC1, CFTR, SERPINB1 ALDH1A1 1261/4885MEN1 3719/4885POLB 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.